JP2019534710A - インターロイキン２に結合する抗体およびその使用 - Google Patents

インターロイキン２に結合する抗体およびその使用 Download PDF

Info

Publication number
JP2019534710A
JP2019534710A JP2019538102A JP2019538102A JP2019534710A JP 2019534710 A JP2019534710 A JP 2019534710A JP 2019538102 A JP2019538102 A JP 2019538102A JP 2019538102 A JP2019538102 A JP 2019538102A JP 2019534710 A JP2019534710 A JP 2019534710A
Authority
JP
Japan
Prior art keywords
antibody
amino acid
seq
light chain
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019538102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534710A5 (enExample
Inventor
マリナ ルール
マリナ ルール
ルービンシュタインマーク
マーク ルービンシュタイン
ハッサン イッサフラス
ハッサン イッサフラス
リュウェリン ラオ
リュウェリン ラオ
ウー リー
ウー リー
ダニエル エイチ． ベディンガー
ダニエル エイチ． ベディンガー
クリスティン カムフィールド リンド
クリスティン カムフィールド リンド
アグネス チョピン ホームズ
アグネス チョピン ホームズ
トシヒコ タケウチ
トシヒコ タケウチ
ローレン シュワイマー
ローレン シュワイマー
ホア ジャン
ホア ジャン
アメール エム． ミルザ
アメール エム． ミルザ
カーク ダブリュー． ジョンソン
カーク ダブリュー． ジョンソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MUSC Foundation for Research and Development
Original Assignee
MUSC Foundation for Research and Development
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MUSC Foundation for Research and Development filed Critical MUSC Foundation for Research and Development
Publication of JP2019534710A publication Critical patent/JP2019534710A/ja
Publication of JP2019534710A5 publication Critical patent/JP2019534710A5/ja
Priority to JP2022105725A priority Critical patent/JP2022141693A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019538102A 2016-09-28 2017-09-28 インターロイキン２に結合する抗体およびその使用 Pending JP2019534710A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022105725A JP2022141693A (ja) 2016-09-28 2022-06-30 インターロイキン２に結合する抗体およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662401158P 2016-09-28 2016-09-28
US62/401,158 2016-09-28
US201662421038P 2016-11-11 2016-11-11
US62/421,038 2016-11-11
PCT/US2017/053880 WO2018064255A2 (en) 2016-09-28 2017-09-28 Antibodies that bind interleukin-2 and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022105725A Division JP2022141693A (ja) 2016-09-28 2022-06-30 インターロイキン２に結合する抗体およびその使用

Publications (2)

Publication Number Publication Date
JP2019534710A true JP2019534710A (ja) 2019-12-05
JP2019534710A5 JP2019534710A5 (enExample) 2020-11-12

Family

ID=60117762

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019538102A Pending JP2019534710A (ja) 2016-09-28 2017-09-28 インターロイキン２に結合する抗体およびその使用
JP2022105725A Pending JP2022141693A (ja) 2016-09-28 2022-06-30 インターロイキン２に結合する抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022105725A Pending JP2022141693A (ja) 2016-09-28 2022-06-30 インターロイキン２に結合する抗体およびその使用

Country Status (13)

Country Link
US (2) US10858428B2 (enExample)
EP (1) EP3518969A2 (enExample)
JP (2) JP2019534710A (enExample)
KR (1) KR20190057113A (enExample)
CN (1) CN110087681A (enExample)
AU (1) AU2017335771A1 (enExample)
BR (1) BR112019005944A2 (enExample)
CA (1) CA3038679A1 (enExample)
IL (1) IL265323A (enExample)
MX (1) MX2019003543A (enExample)
PH (1) PH12019500643A1 (enExample)
WO (1) WO2018064255A2 (enExample)
ZA (1) ZA201901892B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019005944A2 (pt) * 2016-09-28 2019-06-11 Musc Foudation For Res Development anticorpos que se ligam à interleucina 2 e usos dos mesmos
JP7537766B2 (ja) * 2019-08-09 2024-08-21 国立研究開発法人理化学研究所 人工アジュバントベクター細胞と免疫賦活化剤との併用
WO2021161287A2 (en) 2020-02-16 2021-08-19 Aulos Bioscience, Inc Engineered anti-il-2 antibodies
CN111499746B (zh) * 2020-04-28 2020-11-24 优睿赛思(武汉)生物科技有限公司 一种针对人白介素-2的高亲和力兔单克隆抗体及其应用
CN114441763A (zh) * 2020-10-30 2022-05-06 江苏恒瑞医药股份有限公司 一种白细胞介素2的检测方法
WO2022109477A1 (en) * 2020-11-23 2022-05-27 University Of Florida Research Foundation, Incorporated Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
CN119790064A (zh) * 2022-08-23 2025-04-08 马斯得生物有限公司 Il2变体和包括该il2变体的蛋白复合体
CN115850471A (zh) * 2022-10-13 2023-03-28 深圳市百士通科技开发有限公司 一种抗人il-2单克隆抗体及其应用
CN118440194B (zh) * 2024-05-23 2024-11-26 武汉爱博泰克生物科技有限公司 用于检测鼠白介素-2的抗体、抗体对及检测试剂或试剂盒

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109212A1 (en) * 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
CA2067194C (en) 1989-10-05 2003-03-18 Glenn Kawasaki Cell-free synthesis and isolation of novel genes and polypeptides
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE439435T1 (de) 1991-03-01 2009-08-15 Dyax Corp Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
DE69233204T2 (de) 1991-12-13 2004-07-15 Xoma Corp., Berkeley Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6664114B1 (en) 1992-08-03 2003-12-16 Sapidyne Instruments, Inc. Solid phase assay for detection of ligands
US5723287A (en) 1992-09-22 1998-03-03 Medical Research Council Recombinant viruses displaying a nonviral polypeptide on their external surface
US6054287A (en) 1994-05-27 2000-04-25 Methodist Hospital Of Indiana, Inc. Cell-type-specific methods and devices for the low temperature preservation of the cells of an animal species
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
DK1354034T3 (da) 2000-11-30 2008-03-25 Medarex Inc Transgene transchromosomale gnavere til fremstilling af humane antistoffer
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
MXPA04009418A (es) 2002-03-29 2005-06-08 Schering Corp Anticuerpos monoclonales humanos par interleucina-5, y metodos y composiciones que comprenden los mismos.
WO2006128690A1 (en) * 2005-06-01 2006-12-07 Micromet Ag Anti-il2 antibodies
ATE416271T1 (de) * 2005-06-03 2008-12-15 M Real Oyj Verfahren und vorrichtung zur mechanischen entfaserung von holz
AU2007214426A1 (en) 2006-02-16 2007-08-23 Nascent Biologics, Inc. Methods for improving immune function and methods for prevention or treatment of disease in a mammalian subject
CA2656700A1 (en) 2006-07-06 2008-01-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
CU23734A1 (es) 2009-11-27 2011-11-15 Centro Inmunologia Molecular Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
KR20200070407A (ko) 2010-11-12 2020-06-17 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
LT3075745T (lt) 2011-02-10 2018-11-26 Roche Glycart Ag Mutavę interleukino-2 polipeptidai
AU2012261933B2 (en) 2011-06-03 2017-06-15 Xoma Technology Ltd. Antibodies specific for TGF-beta
WO2013177187A2 (en) 2012-05-22 2013-11-28 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
WO2014100014A1 (en) 2012-12-17 2014-06-26 The Board Of Trustees Of The Leland Stanford Junior University Super-2 complexes with antibody to augment il-2 therapy
US10826982B2 (en) 2013-01-10 2020-11-03 Nxp Usa, Inc. Packet processing architecture and method therefor
PE20161324A1 (es) 2014-02-06 2016-11-25 Hoffmann La Roche Proteinas de fusion de interleucina-2 y usos de las mismas
JP6592505B2 (ja) 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−２のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
CN106604932B (zh) * 2014-07-10 2024-12-10 苏黎世大学 人白细胞介素-2的免疫刺激单克隆抗体
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
AU2015308527C1 (en) 2014-08-29 2021-07-15 F. Hoffmann-La Roche Ag Combination therapy of tumor-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
EP3365369A1 (en) * 2015-10-23 2018-08-29 Pfizer Inc Anti-il-2 antibodies and compositions and uses thereof
BR112018014150A2 (en) * 2016-01-11 2018-12-11 Novartis Ag immunostimulating humanized monoclonal antibodies to human interleukin-2, and fusion proteins thereof
BR112019005944A2 (pt) * 2016-09-28 2019-06-11 Musc Foudation For Res Development anticorpos que se ligam à interleucina 2 e usos dos mesmos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109212A1 (en) * 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
IMMUNITY, vol. 42, JPN6021030380, 2015, pages 815 - 825, ISSN: 0004568535 *
MABS, vol. Volume 3 Issue 3, JPN6021030381, 2011, pages 243 - 252, ISSN: 0004568536 *
耳鼻, vol. 60(補1), JPN6021030383, 2014, pages 63 - 69, ISSN: 0004568538 *
薬剤学, vol. 74(1), JPN6021030382, 2014, pages 4 - 11, ISSN: 0004568537 *

Also Published As

Publication number Publication date
US10858428B2 (en) 2020-12-08
PH12019500643A1 (en) 2019-07-29
WO2018064255A2 (en) 2018-04-05
MX2019003543A (es) 2019-06-17
US12234285B2 (en) 2025-02-25
US20180094053A1 (en) 2018-04-05
JP2022141693A (ja) 2022-09-29
EP3518969A2 (en) 2019-08-07
WO2018064255A3 (en) 2018-06-07
IL265323A (en) 2019-05-30
US20210188969A1 (en) 2021-06-24
ZA201901892B (en) 2019-12-18
KR20190057113A (ko) 2019-05-27
AU2017335771A1 (en) 2019-02-28
BR112019005944A2 (pt) 2019-06-11
CN110087681A (zh) 2019-08-02
CA3038679A1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
US12234285B2 (en) Antibodies that bind interleukin-2 and uses thereof
JP7242760B2 (ja) ＴＧＦ－β及びＰＤ－１の阻害物質を使用する癌の治療法
CN111526888B (zh) 抗tigit抗体及其作为治疗和诊断的用途
KR102372274B1 (ko) 세포독성 t-림프구-관련 단백질 4 (ctla-4)에 대한 신규의 단일클론 항체
EP2984107B1 (en) Bispecific antibodies against cd3-epsilon and ror1
JP2022065073A (ja) Ｂｃｍａ結合分子及びその使用方法
KR20220050971A (ko) 신규 항-cd39 항체
JP7727086B2 (ja) 抗ｐｖｒｉｇ／抗ｔｉｇｉｔ二重特異性抗体及び応用
US20250179172A1 (en) Cd5 antibody and use thereof
JP2017532290A (ja) Ｃｄ３イプシロンおよびｂｃｍａに対する二特異性抗体
EP3632932A1 (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
JP2023513200A (ja) 抗ｃｄ３および抗ｃｄ１２３二重特異性抗体およびその使用
US20200317817A1 (en) Parathyroid Hormone Receptor 1 (PTH1R) Antibodies and Uses Thereof
JP2024533488A (ja) 抗ヒトｃｄ３抗体及びその応用
CN118251419A (zh) 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途
WO2022206753A1 (zh) GARP/TGFβ1抗体及其应用
US20240109973A1 (en) Cd40 binding molecules and uses thereof
JP7104458B2 (ja) リンパ球活性化遺伝子－３（ｌａｇ－３）結合抗体およびその使用
TWI833227B (zh) 靶向pd-l1和cd73的特異性結合蛋白及其應用
JP2021513357A (ja) ネコＭｃＤｏｎｏｕｇｈ肉腫（ＦＭＳ）様チロシンキナーゼ３受容体リガンド（ＦＬＴ３Ｌ）に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200925

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200925

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210301

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210811

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220630

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220630

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220707

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220711

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220909

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220914

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231218